Treatment involves adult patients with relapsed or refractory diffuse large B-cell lymphoma
Gilead Sciences has announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) for routine commissioning on the NHS across England.
It concerns the treatment of particular adults with certain forms of lymphoma – specifically patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have already been treated with two or more systemic therapies.